跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ISRCTN18709765
ISRCTN18709765已完成未知

A decision explorer for women deciding about breast cancer treatments: BresDex trial

Cardiff University (UK)0 个研究点目标入组 148 人开始时间: 2010年4月29日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
148
研究概览入排标准研究者记录与标识符相似试验

研究概览

研究设计

研究类型
Observational

入排标准

性别
Female

入选标准

  • •Patient needs assessment:
  • •1. Women diagnosed as having early breast cancer within 3 to 6 months of their 1st therapeutic treatment
  • •2. Given an option of either breast conservation surgery or mastectomy
  • •Professional needs assessment:
  • •Data will be collected from a purposive sample of NHS based individuals recruited to represent a number of multidisciplinary breast teams and their constituent members; breast surgeons, breast care nurses, breast oncologists, opinion leaders with expertise in the surgical, oncological and psycho-oncological perspectives of breast cancer management including a representative of the Association of Breast Surgeons at the British Association of Surgical Oncology (BASO).
  • •1. Willingness to be interviewed about this area of clinical practice
  • •2. Experience of directly dealing with women facing treatment decisions for early breast cancer
  • •Prototype development:
  • •1. Women (any age) diagnosed as having early breast cancer (stage 1)
  • •2. Given an option of either breast conservation surgery or mastectomy
  • •3. Within 3 to 6 months of their first therapeutic treatment
  • •External key informants including the health care professionals identified and consented in Step 3 and those nominated by the Study Management Group who agree to provide formative advice will also be consulted during the prototype development. These key informants must show a willingness to participate in the development and evaluation of a prototype of the decision explorer.
  • •Evaluation of completed decision explorer:
  • •1. Women (any age) diagnosed as having early breast cancer (stage 1 and 2)
  • •2. Surgical treatment options

排除标准

  • •Patient needs assessment:
  • •1. Women beyond 6 months of their initial therapeutic treatment who have chosen to undergo either breast conservation surgery or mastectomy
  • •2. Women recently diagnosed with breast cancer who were not given surgical treatment options
  • •3. Any conditions or illness that preclude the completion of a semi-structured interview about the issue of breast cancer, i.e. mental illness such as severe anxiety or depression likely to be exacerbated by discussing the diagnosis
  • •4. Any conditions precluding the ability to give informed consent to participate in the study
  • •Professional needs assessment:
  • •1. For the sample of NHS-based multidisciplinary team members, health care professionals who are not permanent specialist members of specialist multidisciplinary breast team
  • •2. Individuals not routinely involved in discussing treatment options with patients newly diagnosed with breast cancer
  • •Prototype development:
  • •1. Women beyond 6 months of their initial therapeutic treatment who have chosen to undergo either breast conservation surgery or mastectomy
  • •2. Women recently diagnosed with breast cancer who were not given surgical treatment options
  • •3. Any conditions or illness that preclude the completion of a semi-structured interview about the issue of breast cancer, i.e. mental illness such as severe anxiety or depression likely to be exacerbated by discussing the diagnosis
  • •4. Any conditions precluding the ability to give informed consent to participate in the study
  • •Evaluation of completed decision explorer:
  • •1. Women beyond their initial therapeutic surgical treatment who have chosen to undergo either breast conservation surgery or mastectomy
  • •2. Women recently diagnosed with breast cancer who were not given surgical treatment options
  • •3. Any conditions or illness that preclude the completion of a semi-structured interview about the consideration of treatment choices for early breast cancer, i.e. mental illness such as severe anxiety or depression likely to be exacerbated by discussing the diagnosis
  • •4. Conditions precluding the ability to give informed consent to participate in the study
  • •5. Health care professionals who are not involved in the care and therefore the recruitment of patients asked to use the decision explorer in this step

研究者

发起方
Cardiff University (UK)

相似试验

进行中（未招募）
1 期
Estudio de fase IIb para seleccionar una dosis oral diaria de GSK2248761 en combinación con tenofovir/emtricitabina o abacavir/lamivudina, en sujetos adultos infectados por el VIH-1 que no han recibido tratamiento antiretroviral previoSujetos adultos infectados por el VIH-1 que no han recibido tratamiento antiretroviral previo.MedDRA version: 12.1Level: LLTClassification code 10008922Term: Chronic infection with HIV
EUCTR2010-018487-16-ESaboratorios ViiV Healthcare S
进行中（未招募）
1 期
Estudio fase IIb para la selección de una dosis oral una vez al día de GSK2248761 en sujetos adultos infectados por el VIH 1 tratados previamente con antirretrovirales con resistencia a inhibidores de la transcriptasa inversa no análogos de nucleósidos (ITINN).Sujetos adultos infectados por el VIH 1 tratados previamente con antirretroviralesMedDRA version: 12.1Level: LLTClassification code 10008922Term: Chronic infection with HIVMedDRA version: 13Level: LLTClassification code 10008922Term: Infección crónica con VIH
EUCTR2010-018532-40-ESaboratorios ViiV Healthcare S
进行中（未招募）
不适用
Estudio de Fase II que compara brivudina solución oftálmica al 0,1% con aciclovir pomada oftálmica al 3% en el tratamiento de pacientes con queratitis herpética dendrítica. A Phase II trial comparing Brivudin 0.1% ophthalmic solution with Aciclovir 3 % ophthalmic ointment in the treatment of patients with herpetic dendritic keratitisQueratitis herpética dentriticaHerpetic dendritic keratitisMedDRA version: 12.0Level: LLTClassification code 10012307Term: Dendritic keratitis
EUCTR2009-010971-26-ESMenarini Ricerche S.p.A.50
进行中（未招募）
不适用
Estudio fase II, aleatorizado, para valorar la eficacia de paclitaxel en monoterapia vs paclitaxel + cetuximab (ERBITAX) en pacientes con carcinoma escamoso de cabeza y cuello recurrente y/o metastásico que han progresado a una primera línea de quimioterapia tipo EXTREME.Randomized Phase II, study to evaluate the efficacy of Paclitaxel in monotherapy vs Paclitaxel + Cetuximab (Erbitax) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma that has progressed to extreme-type first line chemotherapy - EXTAXTratamiento del cáncer de células escamosas de cabeza y cuello recurrente y/o metastásico tras progresión a una primera línea de tratamiento EXTREME en pacientes que estén en tratamiento con cetuximab en mantenimientoMedDRA version: 8.1Level: LLTClassification code 10060121
EUCTR2010-019061-28-ESGrupo Español de Tratamiento de Tumores de Cabeza y Cuello80
进行中（未招募）
1 期
Estudio de fase 2, aleatorizado, de 12 semanas de duración, doble ciego, controlado con comparador activo, en el que se evalúa LY2599506, administrado en monoterapia o combinado con metformina, en pacientes con diabetes mellitus tipo 2A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes Mellitus - GMAJDiabetes Mellitus Tipo 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitus
EUCTR2009-016007-39-ESilly S.A.192